The switching spiral: A triumph of hope over benefit?

AIDS Reader

Volumn 12, Issue 4, 2002, Pages 147-150

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Lipodystrophy; Switching regimens

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ANEMIA; DIARRHEA; DRUG CHOICE; DRUG INDUCED DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LIPOATROPHY; METABOLIC DISORDER; NEPHROLITHIASIS; NEUROPATHY; OUTCOMES RESEARCH; REVIEW;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; DRUG COMBINATIONS; DRUG INTERACTIONS; HIV; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; QUALITY OF LIFE; RISK ASSESSMENT; WEIGHT LOSS;

EID: 0036257393     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Protease inhibitor class-sparing maintenance therapy with abacavir (ABC) + lamivudine (3TC) + zidovudine (ZDV) in patients with long-term suppression of HIV-1 RNA
2. Switching protease inhibitors to nevirapine (NEV), efavirenz (EFA) or abacavir (ABA): A randomized, multicenter, open-label, simplification trial
3. Comparison of nucleoside reverse transcriptase inhibitor (NRTI) and HIV protease inhibitor (PI) effects on metabolic and mitochondrial functions in an adipocyte cell culture model
4. Stavudine versus zidovudine and the development of lipodystrophy
5. Switching stavudine or zidovudine to abacavir for HIV lipoatrophy: A randomised, controlled, open-label, multicentre, 24-week study
6. A randomised, controlled, open-label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-Week data
7. Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV)
8. A randomised open label study of substitution of PI/NNRTI, d4T or both in persons with virologic suppression and significant metabolic changes and/or clinical fat redistribution
9. Incidence and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients